Breast Cancer Treatment Innovator Atossa Genetics Announcing Preliminary Results from Phase 1 Study October 25
Seattle, WA based Atossa Genetics Inc. (NasdaqCM: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions will host a conference call on October 25, 2017 at 10 am EDT to discuss preliminary results from its Phase 1 dose escalation study of its proprietary oral Endoxifen. Endoxifen is an active metabolite of the FDA-approved drug tamoxifen, which is currently used to treat breast cancer and for breast cancer prevention in high-risk patients.
The objectives of Atossa’s double-blinded, placebo-controlled, Phase 1 study of 48 healthy female subjects were to assess the pharmacokinetics of proprietary formulations of both oral and topical Endoxifen dosage forms as single (oral) and repeat (oral and topical) doses, as well as to assess safety and tolerability. The study was conducted in two parts based on route of administration. Preliminary results from the topical arm of the study were announced on September 14, 2017.
To listen to the call by phone, interested parties within the U.S. should call 1-844-824-3830 and International callers should call 1-412-317-5140. All callers should ask for the Atossa Genetics conference call. The conference call will also be available through a live webcast at www.atossagenetics.com. Details for the webcast may be found on the Company’s IR events page at http://ir.atossagenetics.com/ir-calendar.
A replay of the call will be available approximately one hour after the end of the call through November 24, 2017. The replay can be accessed via Atossa’s website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll-Free at 855-669-9658.
The American Cancer Society (ACS) estimates that approximately 250,000 women will be diagnosed with breast cancer in the United States this year and that approximately 40,000 will die from the disease. It is the second leading cause of cancer death in American women. Although about 100 times less common than women, breast cancer also affects men. The ACS estimates that the lifetime risk of men getting breast cancer is about 1 in 1,000; 2,470 new cases of invasive breast cancer will be diagnosed; and 460 men will die from breast cancer in 2017.
October’s Brеаѕt Cаnсеr Awareness іѕ an іmроrtаnt mоnth fоr аll women and serves аѕ a reminder tо prevent more women frоm ѕuffеrіng while аlѕо improving thе аwаrеnеѕѕ оf Hеаlth Wеllnеѕѕ. It is time to keep focused and be aware!
Shares of ATOS today traded an amazing 69.02 Million shares and closed at $1.22 up 96.77% after hitting a high of $1.50. Since we added ATOS to as a Featured Company on July 2017 post the company’s shares hitting a 52-week low of $.32 we have seen a strong rise in both volume and share price. prior to today’s amazing volume shares had more than doubled and the average daily volume has increased significantly to 1.59 million/day.